Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE II: Gardasil for cervical cancer prevention
NCT00092534Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2002
- Primary completion
- Jul 2007
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in Cervical Cancer (CC), genital warts, sponsored by Merck & Co.. Started Jun 2002; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
Cervical Cancer (CC)genital warts
Beyond the preview
Go deeper on NCT00092534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092534.